Bayer AG’s share price, which hovered near €42.9 on January 19, 2026, has begun to rebound after a protracted period of legal uncertainty surrounding its glyphosate business. The latest developments in the United States Supreme Court and the prospect of a settlement in the long‑running litigation appear to be the main drivers behind the recent uptick.

Supreme Court Review Signals Potential Turning Point

A series of articles published on January 21, 2026, highlight that the U.S. Supreme Court has taken up a review of the glyphosate case that has haunted Bayer since the 2018 acquisition of Monsanto. Sources on finance.de, boerse‑express.com, and finanzen100.de note that the Court’s examination could lead to a “legal relief” for the company. Analysts point out that a favorable ruling would effectively collapse the “glyphosate knot” that has tied the shares to a steep decline over the last months.

Market Reaction and Technical Support

The immediate market reaction was a modest lift in the Bayer share price. The stock traded at €42.55 earlier in the day, reflecting a 1.5 % decline from the previous close but remaining well above the 52‑week low of €18.38. The 52‑week high, currently €44.98, is now within reach as the market begins to digest the possibility of a Supreme Court decision.

Investment platforms such as XTB and EQS-PVR have noted the “potentially decisive” nature of this legal development. While some analysts caution that the outcome remains uncertain, many investors see the Supreme Court review as a catalyst for a new bullish phase.

Bayer’s legal exposure, stemming from the Monsanto acquisition, had previously been described as a “milliardenschweres Rechtsrisiko” (billions‑worth legal risk). The flood of lawsuits alleging the carcinogenicity of glyphosate has weighed heavily on the company’s valuation, as reflected in the negative price‑earnings ratio of –213.85. A Supreme Court decision that limits or dismisses these claims would substantially reduce this liability and improve the firm’s earnings outlook.

Corporate Strategy and Future Outlook

Beyond the legal dimension, Bayer’s broader corporate strategy remains focused on its health‑care and agricultural product lines. The company continues to produce a diverse portfolio that includes aspirin, antibiotics, cardiovascular and oncology drugs, as well as diagnostic and animal‑health products. The potential easing of the glyphosate litigation burden could free management to reinvest in these core areas, further strengthening the company’s long‑term position.

Summary

  • Supreme Court Review: Potential to collapse glyphosate litigation burden.
  • Stock Movement: Recent decline to €42.55; possible rebound toward €44.98.
  • Legal Impact: Reduction of billions‑level liability could improve P/E ratio.
  • Strategic Focus: Health‑care and agriculture remain key growth areas.

The next few weeks will be critical as the Supreme Court’s decision becomes clear. Investors will be closely watching how this legal milestone translates into corporate performance and share price dynamics.